We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Arecor Therapeutics
H121 results underline quality of management executionAllergy Therapeutics
VLP Peanut heading towards US Phase I studiesRedx Pharma
ESMO 2021: RXC004 monotherapy Phase I study resultsArecor Therapeutics
AT278 Phase I delivers better than expected resultsArecor Therapeutics
Formulating the recipe for successRedx Pharma
Kadmon acquisition has read across for RXC007Redx Pharma
All that Jazz: $3m milestone boosts cash and confidenceNexstim
Accelerated protocols could be a game changerAvacta
Lead therapeutic asset AVA6000 enters the clinicHUTCHMED
Strategic collaboration for Tazverik in Greater China